跳至主要内容
临床试验/NCT02683954
NCT02683954已完成不适用

The Association Bet Endometriosis, Obesity and nesfatin1

Ain Shams Maternity Hospital0 个研究点目标入组 60 人开始时间: 2014年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
主要终点
Serum Nesfatin 1

研究概览

简要总结

The association between endometriosis, obesity and nesfatin1.

详细描述

All women in this study were subjected to all of the following:

  1. Verbal consent was obtained.

  2. History taking:

  3. Personal history.

  4. Menstrual history.

  5. Use of contraception.

  6. Use of any hormonal treatment in the three months prior to the laparoscopy.

  7. History of infertility and its duration and type.

  8. Sexual history.

  9. Past history.

  10. Complete physical examination: general, abdominal and local gynecological examination.

  11. Complete preoperative workout for laparoscopy was done.

  12. Laparoscopy was done postmenstrual, during follicular phase. All patients gave an informed consent and were fasting for at least 8 hours prior to the laparoscopy, and general anesthesia was used for all patients.

The pelvis and its structures were observed and checked for presence of endometriotic lesions (uterus, tubes, ovaries and ovarian fossae, uterosacral ligaments, Douglas pouch, uterovesical pouch, broad ligaments and lateral pelvic walls).

The Endometriotic patients were then classified into stages I-IV according to the revised American Fertility Society scoring system for endometriosis. 6. Venous samples for measurement of nesfatin-1 were taken by venipuncture from patients during the laparoscopy procedure immediately after initial evaluation and before any intervention. 7. Biopsy from lesions suspected as endometriosis was taken during laparoscopy and sent to histopathology for confirmation. 8. The blood samples were centrifuged immediately after their collection at 5000 rpm for 10 min and serum samples were stored at -20 °C until analysis.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
20 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women in reproductive age group scheduled for laparoscopy for any indication.

排除标准

  • Women subject to any hormonal therapy in the last 3 months.
  • Women with chronic endocrine disease like diabetes mellitus.
  • Women diagnosed with pelvic inflammatory disease (PID).
  • Severe medical disorder that prohibits the laparoscopic procedure, such as cardiovascular disease and pulmonary disease.

结局指标

主要结局

Serum Nesfatin 1

时间窗: 24 hours

Venous samples for measurement of nesfatin-1 were taken by venipuncture from patients during the laparoscopy procedure immediately after initial evaluation and before any intervention.The blood samples were centrifuged immediately after their collection at 5000 rpm for 10 min and serum samples were stored at -20 °C until analysis. Nesfatin-1 was measured by Enzyme-Linked Immuno Sorbent Assay "ELISA" technique using commercially available kits (Boster Biological Technology Human Nesfatin-1 ELISA kits, Catalog number EK1138, USA) in the Central Labs of Ain Shams University Hospitals.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Amr Ahmed Mahmoud Riad

Lecturer of obstetrics and gynecology

Ain Shams Maternity Hospital

相似试验